BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19127950)

  • 1. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
    Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G
    Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and developing therapeutic agents in the treatment of Chagas disease.
    Apt W
    Drug Des Devel Ther; 2010 Sep; 4():243-53. PubMed ID: 20957215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in parasitemia evaluated using the modified Strout method in patients with acute Chagas disease under treatment].
    Castro C; Emanuel A
    Rev Soc Bras Med Trop; 1988; 21(4):177-80. PubMed ID: 3152133
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential new clinical therapies for Chagas disease.
    Bustamante JM; Tarleton RL
    Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Chagas' disease in the mouse. IV. Effect of trypanocidal drugs.
    Laguens RP; Cabeza Meckert P; Chambó JG; Gelpi R
    Medicina (B Aires); 1983; 43(2):126-30. PubMed ID: 6420640
    [No Abstract]   [Full Text] [Related]  

  • 8. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
    Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
    Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and Clinical Treatment of Chagas Disease: A Review.
    Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allopurinol in the treatment of chronic Chagas' disease].
    Meirovich CI; Montrull HL; Gallerano RH; Sosa RR
    Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina].
    Sosa Estani S; Segura EL
    Medicina (B Aires); 1999; 59 Suppl 2():166-70. PubMed ID: 10668259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitrypanosomal agents: treatment or threat?
    Issa VS; Bocchi EA
    Lancet; 2010 Sep; 376(9743):768; author reply 768-9. PubMed ID: 20816538
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
    Cevey ÁC; Mirkin GA; Donato M; Rada MJ; Penas FN; Gelpi RJ; Goren NB
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):378-387. PubMed ID: 29040909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
    Castro JA; de Mecca MM; Bartel LC
    Hum Exp Toxicol; 2006 Aug; 25(8):471-9. PubMed ID: 16937919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.
    González NL; Moscatelli G; Moroni S; Ballering G; Jurado L; Falk N; Bochoeyer A; Goldsman A; Grippo M; Freilij H; Garcia Bournissen F; Chatelain E; Altcheh J
    PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010968. PubMed ID: 36534647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.